Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Monoclonal Antibodies For Therapy Prevention And In Vivo Diagnosis Of Human Disease PDF full book. Access full book title Monoclonal Antibodies For Therapy Prevention And In Vivo Diagnosis Of Human Disease.
| Author | : Prevention and In Vivo Diagnosis of Human Disease (1989: Utrecht Symposium on Monoclonal Antibodies for Therapy (the Netherlands)) |
| Publisher | : |
| Total Pages | : 246 |
| Release | : 1989 |
| Genre | : |
| ISBN | : |
| Author | : |
| Publisher | : |
| Total Pages | : 268 |
| Release | : 1990 |
| Genre | : Medical |
| ISBN | : |
| Author | : |
| Publisher | : |
| Total Pages | : 246 |
| Release | : 1990 |
| Genre | : |
| ISBN | : |
| Author | : Kenneth A. Foon |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 171 |
| Release | : 2012-12-06 |
| Genre | : Medical |
| ISBN | : 1461326273 |
KENNETH A. FOON and ALTON C. MORGAN, JR. Passive immunotherapy using heteroantisera for the treatment of cancer in animals and humans has been studied for over 50 years. Attempts have been made to treat animal tumors with sera from immunized syngeneic, allogeneic, or xenogeneic animals. A number of studies of passive immunotherapy using heterologous antisera in humans have also been performed. These studies have generally been attempted in patients with large tumor burdens, and as would be expected, results have been transient at best. A wide variety of solid tumors as well as leukemias and lym phomas have been treated with antisera raised in sheep, horses, rabbits, and goats. Problems such as anaphylaxis, serum sick ness, and severe cytopenias have been encountered with these antisera. There are a number of potential mechanisms by which unconju gated antibodies might be cytotoxic to tumor cells. Antibodies bound to the cell surface membrane of tumor cells may lead to cell lysis by complement-dependent or antibody-dependent cellu lar cytotoxicity. Circulating tumor cells bound by antibody may be more susceptible to phagocytosis by the reticuloendothelial system. Antibody bound to the cell surface membrane of tumor cells may enhance immunogenicity of the tumor cell leading to activation of the host's immune system.
| Author | : Jack A. Roth |
| Publisher | : Blackwell/Futura |
| Total Pages | : 360 |
| Release | : 1986 |
| Genre | : Medical |
| ISBN | : |
| Author | : J. R. Birch |
| Publisher | : Wiley-Liss |
| Total Pages | : 368 |
| Release | : 1995-03-02 |
| Genre | : Medical |
| ISBN | : |
General introduction. Applications. Genetic manipulation and expression of antibodies. Modification of antibodies by chemical methods. The production of monoclonal antibodies. Blosafety considerations. Antibody patents.
| Author | : Suresh C. Srivastava |
| Publisher | : Springer |
| Total Pages | : 908 |
| Release | : 1988-09 |
| Genre | : Medical |
| ISBN | : |
The advent of hybridoma technology leading to the successful produc tion of monoclonal antibodies against a variety of tumor-associated antigens has, during the last decade, provided a very powerful tool for research and clinical investigations. These highly specific reagents have essentially replaced the polysera of the earlier days. The successful demonstration of the many wide ranging capabilities of the monoclonal antibody technique has already begun to exert an enormous impact on diverse areas of research in basic science and medicine. In particular, the potential of monoclonal antibodies to serve as carriers for selective targeting of radionuclides to tumors for diagnosis or therapy, has stimulated an intense surge of research interest and even revived hopes of realizing Ehrlich's concept of the "magic bullet". Indeed, the technology appears to be on the threshold of a revolution in diagnosing and treating malignant disease. Much work remains to be done, however, and even though the progress has been impressive, results to date have shown only moderate success. There is no question that the limited success we have achieved thus far is merely a prelude to the many more exciting developments yet to come.
| Author | : Martin Rosenberg |
| Publisher | : |
| Total Pages | : 440 |
| Release | : 1994 |
| Genre | : Monoclonal antibodies |
| ISBN | : |
It has been almost 20 years since the discovery by Kohler and Milstein of the technology to produce monoclonal antibodies (MAbs), a discovery that promised revolutionary changes in research, clinical diagnosis and human therapy. From today's perspective, it is fair to conclude that this promise has been realized in two areas of the three. As research tools, MAbs have been invaluable: their ability to selectively bind and localize specific antigens, detect and identify new ligands and their receptors, and agonize and/or antagonize specific molecular interactions continues to provide a useful and enabling technology to basic research endeavors. Similarly, MAbs have demonstrated enormous practical impact as diagnostic tools. Recent advances in clinical diagnostic medicine continue to rely heavily on the use of MAb-based reagents for detecting and localizing antigens of clinical import. In contrast, however, MAbs have not proven to have major impact on human disease therapy. With the single exception of an immunosup pressive MAb against the T-cell antigen, CD3, MAbs have as yet found few meaningful applications as therapeutic agents. During the 1980s, a set of technologies to clone, modify and express genes encoding MAbs was developed. These breakthroughs permitted MAbs to be genetically engineered which consequently gave them the potential to greatly enhance their therapeutic utility as well as significantly expand their research and diagnostic applications. New MAbs, fragments of MAbs, bispecific MAbs, single-chain MAbs, and fusions of MAbs with other gene products became available for study.
| Author | : Silvio Folli |
| Publisher | : |
| Total Pages | : 244 |
| Release | : 1992 |
| Genre | : |
| ISBN | : |
| Author | : National Research Council |
| Publisher | : National Academies Press |
| Total Pages | : 74 |
| Release | : 1999-05-06 |
| Genre | : Medical |
| ISBN | : 0309173051 |
The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.
